XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Share-Based Payments - SOP 2015 (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Jun. 23, 2017
Aug. 25, 2016
Sep. 23, 2015
Apr. 02, 2015
Additional disclosures            
Share-based compensation expense $ 1,907 $ 1,244        
SOP 2015            
Options            
Outstanding at beginning of year (in shares) 2,842,913          
Forfeited (in shares) (22,664)          
Outstanding at end of year (in shares) 2,820,249          
Vested and exercisable at end of year (in shares) 1,988,358          
Weighted average exercise price in $ per share            
Outstanding balance at beginning of year (in dollars per share) $ 8.34          
Forfeited (in dollars per share) 9.86          
Outstanding balance at end of year (in dollars per share) 8.33          
Vested and exercisable balance at end of year (in dollars per share) $ 8.12          
Additional disclosures            
Share-based compensation expense $ 900 $ 900        
SOP 2015 | Stock Options            
Share-Based Payments            
Vesting period 4 years          
Exercise period 10 years          
Additional disclosures            
Weighted-average remaining contractual life 7 years 2 months 12 days          
Total unrecognized compensation related to unvested options $ 4,400          
Recognition period 1 year 10 months 24 days          
SOP 2015 | Stock Options | Vesting period, year one            
Share-Based Payments            
Vesting period 1 year          
Percentage that vests during the period 25.00%          
SOP 2015 | Stock Options | Vesting period, years 2-4            
Share-Based Payments            
Percentage that vests during the period 75.00%          
Monthly vesting percentage 2.083%          
Nabriva Therapeutics AG ("Nabriva Austria") | Redomiciliation Transaction | Common Stock            
Share-Based Payments            
Number of shares to be awarded for each option when exercised     1      
Nabriva Therapeutics AG ("Nabriva Austria") | Redomiciliation Transaction | Ordinary Shares            
Share-Based Payments            
Number of shares to be awarded for each option when exercised     10      
Nabriva Therapeutics AG ("Nabriva Austria") | SOP 2015 | Common Stock            
Share-Based Payments            
Maximum number of shares authorized         177,499 95,000
Nabriva Therapeutics AG ("Nabriva Austria") | SOP 2015 | Ordinary Shares            
Share-Based Payments            
Maximum number of shares authorized       346,235